发明公开
EP2506881A1 COMBINING RADIOIMMUNOTHERAPY AND ANTIBODY-DRUG CONJUGATES FOR IMPROVED CANCER THERAPY
审中-公开
RADIO免疫治疗和抗体药物共轭物的改进癌症治疗相结合
- 专利标题： COMBINING RADIOIMMUNOTHERAPY AND ANTIBODY-DRUG CONJUGATES FOR IMPROVED CANCER THERAPY
- 专利标题（中）： RADIO免疫治疗和抗体药物共轭物的改进癌症治疗相结合
-
申请号： EP10835036.4申请日： 2010-12-01
-
公开(公告)号： EP2506881A1公开(公告)日： 2012-10-10
- 发明人: GOVINDAN, Serengulam V. , GOLDENBERG, David M.
- 申请人： Immunomedics, Inc.
- 申请人地址： 300 American Road Morris Plains, NJ 07950 US
- 专利权人： Immunomedics, Inc.
- 当前专利权人： Immunomedics, Inc.
- 当前专利权人地址： 300 American Road Morris Plains, NJ 07950 US
- 代理机构： Bohmann, Armin K.
- 优先权： US629404 20091202; US266356P 20091203; US292656P 20100106; US322997P 20100412; US323952P 20100414
- 国际公布： WO2011068845 20110609
- 主分类号： A61K51/00
- IPC分类号： A61K51/00 ; A61K39/00
摘要：
Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.
公开/授权文献
信息查询
